The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort
Open accessAbstract
Introduction: Autosomal‐dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have “preclinical” AD. Crenezumab is an antiamyloid monoclonal antibody that binds monomeric and aggregated forms of amyloid β, with highest affinity for oligomers; it is in development for early stages of sporadic AD and for ADAD. Methods: This is a prospective, randomized, double‐blind, placebo‐controlled phase 2 study of the efficacy of crenezumab versus placebo in asymptomatic PSEN1 E280A mutation carriers from family kindreds with ADAD in Colombia. Participants were randomized to receive either crenezumab or placebo for 260 weeks. The study was designed to enroll a planned total of 300 participants, including 200 preclinical mutation carriers (approximately 100 treatment, 100 placebo) and an additional control group of mutation noncarriers from the same family kindreds included to mask mutation carrier status (100 placebo only). The primary outcome is change in the Alzheimer's Prevention Initiative ADAD Composite Cognitive Test Score from baseline to week 260. Secondary outcomes include time to progression to mild cognitive impairment due to AD or dementia due to AD; changes in dementia severity, memory, and overall neurocognitive functioning; and changes in amyloid–positron emission tomography, fluorodeoxyglucose–positron emission tomography, magnetic resonance imaging volumes, and cerebrospinal fluid levels of β amyloid, tau, and p‐tau. Safety and tolerability are assessed. Results: Two hundred fifty‐two participants were enrolled between December 2013 and February 2017. Discussion: We describe the first large‐scale, potentially label‐enabling clinical trial of a preclinical treatment for ADAD. Results from this trial will inform on the efficacy of crenezumab for delaying onset of, slowing decline in, or preventing cognitive impairment in individuals with preclinical ADAD and will foster an improved understanding of AD biomarkers and their relationship to clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Crenezumab is being used in the API ADAD Colombia trial of known mutation carriers (Tariot et al., 2018), whereas active immunization with CAD106 is being used in the API Generation trial of APOE ε4 homozygotes (Lopez Lopez et al., 2019).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Tariot et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Flagged first, then by citations
Research works printed but not linked: 3
- Salloway S., 2014, Amyloid PET imaging results from a study to evaluate the impact of crenezumab on fibrillar amyloid in patients with mild‐to‐moderate Alzheimer's disease., J Prev Alz, 1, 214
- Reiman E.M., 2014, Analysis of amyloid‐β PET changes from the crenezumab anti‐Aβ phase 2 trial using a pre‐specified cerebral white matter reference region‐of‐interest., J Prev Alz, 1, 214
- Sheikh J.I., 1986, Clinical Gerontology: A Guide to Assessment and Intervention, 165
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In 2012, DIAN-TU launched the first prevention trial focusing on two drugs: gantenerumab (against Aβ aggregates) and solanezumab (against soluble Aβ monomers).337 The data showed that gantenerumab had a positive impact on the reduction of cortical amyloid, leading to its further study by an exploratory open-label exte…”
BackgroundAlzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 281
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak‐Vance, M. A., Foroud, T., & Mayeux, R. P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 181
Quiroz, Y. T., Zetterberg, H., Reiman, E. M., Chen, Y., Su, Y., Fox-Fuller, J. T., Garcia, G., Villegas, A., Sepulveda-Falla, D., Villada, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30137-x · Cited by 159
Self-citationPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 161
Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 144
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130
Self-citationPreventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, M. G., Wuu, J., McHutchison, C. A., Postuma, R. B., Boeve, B. F., Petersen, R. C., Ross, C. A., Rosen, H. J., Arias, J. J., Fradette, S., et al. (2021) · Brain · doi:10.1093/brain/awab404 · Cited by 129
Bassil, R., Shields, K., Granger, K., Zein, I., Ng, S., & Chih, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25344-6 · Cited by 106
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Self-citationClinical application of next-generation sequencing to the practice of neurology
Rexach, J. E., Lee, H., Martínez-Agosto, J. A., Nemeth, A. H., & Fogel, B. L. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30033-x · Cited by 117
Immunotherapies for Neurodegenerative Diseases
Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 112
Age at onset in genetic prion disease and the design of preventive clinical trials
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007745 · Cited by 104
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 95
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status
Kaplow, J., Vandijck, M., Gray, J., Kanekiyo, M., Huyck, E., Traynham, C. J., Esquivel, R., Fagan, A. M., & Luthman, J. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12000 · Cited by 81
Jutten, R. J., Papp, K. V., Hendrix, S. B., Ellison, N., Langbaum, J. B. S., Donohue, M., Hassenstab, J. J., Maruff, P. T., Rentz, D. M., Harrison, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12773 · Cited by 84
Self-citationIndividualized clinical management of patients at risk for Alzheimer's dementia
Isaacson, R., Hristov, H., Saif, N., Hackett, K., Hendrix, S. B., Melendez, J., Safdieh, J. E., Fink, M. E., Thambisetty, M., Sadek, G., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.08.198 · Cited by 77
Self-citationAssunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
Kim, S. Y. H., Karlawish, J. H., & Berkman, B. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001451 · Cited by 70
Tau immunotherapies for Alzheimer’s disease
Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y. M., & Decourt, B. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1619694 · Cited by 69
Guthrie, H., Honig, L. S., Lin, H. H., Sink, K. M., Blondeau, K., Quartino, A. L., Dolton, M. J., Carrasco‐Triguero, M., Lian, Q., Bittner, T., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200134 · Cited by 67
Self-citationCacciamani, F., Houot, M., Gagliardi, G. P., Dubois, B., Sikkes, S. A. M., Sánchez‐Benavides, G., Denicolò, E., Molinuevo, J. L., Vannini, P., & Epelbaum, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.697234 · Cited by 63
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
Fuller, J. T., Cronin-Golomb, A., Gatchel, J. R., Norton, D. J., Guzmán-Vélez, E., Jacobs, H. I. L., Hanseeuw, B., Pardilla-Delgado, E., Artola, A., Baena, A., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.6 · Cited by 57
Self-citationMechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez‐Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 59
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 57
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 57
Genetic Phenotypes of Alzheimer’s Disease: Mechanisms and Potential Therapy
Quan, M., Cao, S., Wang, Q., Wang, S., & Jia, J. (2023) · Phenomics · doi:10.1007/s43657-023-00098-x · Cited by 62
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54
Mably, A. J., Liu, W., Donald, J. M. M., Dodart, J., Bard, F., Lemere, C. A., O’Nuallain, B., & Walsh, D. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.008 · Cited by 55
Langlois, C. M., Bradbury, A. R., Wood, E. M., Roberts, J. S., Kim, S. Y. H., Riviere, M., Liu, F., Reiman, E. M., Tariot, P. N., Karlawish, J. H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.013 · Cited by 50
Self-citationKaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 55
Yoshida, K. J., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H. H., Honigberg, L. A., Jin, J. Y., & Quartino, A. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48
Self-citationFrom beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47
Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease
Vannini, P., Hanseeuw, B. J., Gatchel, J. R., Sikkes, S. A. M., Alzate, D., Zuluaga, Y., Moreno, S., Méndez, L., Baena, A. Y., Ospina-Lopera, P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.27472 · Cited by 44
Self-citationAlzheimer’s Disease: Drug Discovery
Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 49
Xiong, C., Luo, J. R., Coble, D. W., Agboola, F., Kukull, W. A., & Morris, J. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12060 · Cited by 42
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Self-citationGrubbs, J. C., Glass, R. I., & Kilmarx, P. H. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.15989 · Cited by 39
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 36
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37
New Insights into the Molecular Bases of Familial Alzheimer’s Disease
D’Argenio, V., & Sarnataro, D. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020026 · Cited by 35
Mortberg, M. A., Vallabh, S. M., & Minikel, E. V. (2022) · Scientific Reports · doi:10.1038/s41598-022-21820-1 · Cited by 35
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Ríos‐Romenets, S., Lopera, F. J., Sink, K. M., Hu, N., Lian, Q., Guthrie, H., Smith, J. P., Cho, W., Mackey, H. M., Langbaum, J. B. S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12109 · Cited by 31
Self-citationPimenova, A. A., & Goate, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104785 · Cited by 34
Llibre‐Guerra, J. J., Li, Y., Allegri, R., Méndez, P. C., Surace, E. I., Rodríguez, J. J. L., Sosa, A. L., Aláez‐Verson, C., Longoria-Ibarrola, E. M., Téllez‐Martínez, J. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12227 · Cited by 29
Self-citationAdvances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 34
Torres, V. L., Vila-Castelar, C., Bocanegra, Y., Baena, A., Guzmán-Vélez, E., Aguirre-Acevedo, D. C., Tirado, V., Munoz, C., Henao, E., Moreno, S., et al. (2021) · Applied Neuropsychology: Adult · doi:10.1080/23279095.2019.1627357 · Cited by 28
Self-citationGhisays, V., Lopera, F. J., Goradia, D. D., Protas, H. D., Malek‐Ahmadi, M. H., Chen, Y., Devadas, V., Luo, J., Lee, W., Baena, A. Y., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102749 · Cited by 30
Self-citationSalemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Alzheimer Disease Clinical Trials Targeting Amyloid
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 27
Vila‐Castelar, C., Tariot, P. N., Sink, K. M., Clayton, D., Langbaum, J. B. S., Thomas, R. G., Chen, Y., Su, Y., Chen, K., Hu, N., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12552 · Cited by 27
Self-citationQuan, M., Zhao, T., Tang, Y., Luo, P., Wang, W., Qin, Q., Li, T., Wang, Q., Fang, J., & Jia, J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0572-2 · Cited by 23
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS
Leoutsakos, J., Gross, A. L., Jones, R. N., Albert, M., & Breitner, J. C. S. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.120 · Cited by 21
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 23
The pathway to secondary prevention of Alzheimer's disease
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12069 · Cited by 20
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
Soto‐Mercado, V., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2021) · Biomolecules · doi:10.3390/biom11121845 · Cited by 18
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 20
Früherkennung der Alzheimer-Krankheit und Ansätze der Prävention
Jessen, F. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02877-2 · Cited by 17
Tatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 16
Soto‐Mercado, V., Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201045 · Cited by 19
Hu, N., Mackey, H. M., & Thomas, R. G. (2021) · Biometrical Journal · doi:10.1002/bimj.202000184 · Cited by 17
Self-citationRamirez-Gomez, L. A., Albers, M. W., Baena, A. Y., Vila‐Castelar, C., Fox‐Fuller, J. T., Sanchez, J. S., Jain, F. A., Albers, A. D., Lopera, F. J., & Quiroz, Y. T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220075 · Cited by 15
Self-citationKim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 15
Reiman, E. M., Pruzin, J. J., Ríos‐Romenets, S., Brown, C., Giraldo, M., Acosta‐Baena, N., Tobón, C., Hu, N., Chen, Y., Ghisays, V., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12843 · Cited by 13
Self-citationImmunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 13
Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer’s Disease
Alanazy, M. H., Alghsoon, K. A., Alkhodairi, A. F., Binkhonain, F. K., Alsehli, T. N., Altukhaim, F., Alkhodair, I. M., & Muayqil, T. A. (2019) · Neurology Research International · doi:10.1155/2019/2570513 · Cited by 12
Soto‐Mercado, V., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220903 · Cited by 12
Mendivil‐Perez, M., Velez‐Pardo, C., Lopera, F. J., Kosik, K. S., & Jiménez-Del-Río, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108957 · Cited by 10
Self-citationWho funds Alzheimer's disease drug development?
Cummings, J. L., Bauzon, J. S., & Lee, G. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12185 · Cited by 9
Bocanegra, Y., Fox‐Fuller, J. T., Baena, A. Y., Guzmán‐Vélez, E., Vila‐Castelar, C., Martinez, J. E., Torrico‐Teave, H., Lopera, F. J., & Quiroz, Y. T. (2020) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617720000673 · Cited by 10
Self-citationAmyloid-Directed Antibodies: Past, Present, and Future
Noorda, K., Noorda, K. J., Sabbagh, M. N., Bertelson, J. A., Singer, J., & Decourt, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240189 · Cited by 9
Imbimbo, B. P., Triaca, V., Imbimbo, C., & Nisticò, R. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.363185 · Cited by 9
Kreiner, G. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.006 · Cited by 9
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
Ríos‐Romenets, S., Acosta‐Baena, N., López, L., Madrigal-Zapata, L., Street, H., Jakimovich, L. J., Langbaum, J. B. S., Cho, W., Reiman, E. M., Tariot, P. N., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.010 · Cited by 9
Self-citationAge of onset in genetic prion disease and the design of preventive clinical trialsPreprint
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/401406 · Cited by 9
Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers
Guzmán‐Vélez, E., Martinez, J. E., Papp, K. V., Baena, A. Y., Vila‐Castelar, C., Artola, A., Schultz, A. P., Bocanegra, Y., Sanchez, J. S., Rentz, D. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010177 · Cited by 8
Self-citationDoğan, M., Eröz, R., Tecellioğlu, M., Gezdirici, A., Çevik, B., & Barış, İ. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220414101251 · Cited by 7
Gomez-Sequeda, N., Mendivil‐Perez, M., Jiménez-Del-Río, M., Lopera, F. J., & Velez‐Pardo, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-39630-4 · Cited by 6
Self-citationScott, M. R., Edwards, N. C., Properzi, M. J., Jacobs, H. I. L., Price, J. C., Lois, C., Farrell, M. E., Hanseeuw, B. J., Thibault, E. G., Rentz, D. M., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231196978 · Cited by 7
Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 7
Metadata
- Authors
- Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., Ramos, C., Espinosa, A., Cho, W., Ward, M., Clayton, D., Friesenhahn, M., Mackey, H., Honigberg, L., Sanabria Bohorquez, S., Chen, K., Walsh, T., Langlois, C., Reiman, E. M., & Initiative, A. P.
- Affiliations
- Banner Alzheimer’s Institute (US)
- Universidad de Antioquia (CO)
- University of California San Diego (US)
- Pentara Corporation Salt Lake City UT USA
- University of Southern California (US)
- Grupo de Neurociencias Universidad de Antioquia, SIU Medellín Colombia
- Genentech, a Member of the Roche Group South San Francisco CA USA
- Genentech (US)
- Corresponding author
- Tariot, Pierre N.
- ORCID
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 150-160
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021543
- OpenAlex
- W2789516300
- Cited by
- 128
- References
- 65
- Citations by year
- 2026: 1 · 2025: 9 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 32 · 2019: 20 · 2018: 7
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Repositorio Digital - Academia Colombiana de Ciencias Exactas, Fisicas y Naturales (submittedVersion, other-oa)
- Funders
- National Institute on Aging (1RFAG041705‐01A1)
- NOMIS Stiftung
- Flinn Foundation (1862)
- AstraZeneca
- H. Lundbeck A/S
- Merck
- Roche
- Amgen
- Biogen
- Elan
- GE Healthcare
- Genentech
- Novartis
- Arizona Department of Health Services
- Foundation for Biomedical Research and Innovation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- autosomal dominant Alzheimer's disease, crenezumab, preclinical Alzheimer's disease, PSEN1 E280A mutation, amyloid-beta oligomers, anti-amyloid monoclonal antibodies, cognitive decline prevention, amyloid PET, cerebrospinal fluid biomarkers, tau protein, familial kindred, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
